These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29074819)

  • 1. Continued Search for Therapies to Favorably Modify Phosphate and FGF23 Levels in CKD.
    Mehta R; Isakova T
    Clin J Am Soc Nephrol; 2017 Dec; 12(12):1911-1913. PubMed ID: 29074819
    [No Abstract]   [Full Text] [Related]  

  • 2. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
    Zhao SJ; Wang ZX; Chen L; Wang FX; Kong LD
    Ann Palliat Med; 2022 Apr; 11(4):1264-1277. PubMed ID: 34775773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.
    Courbon G; Martinez-Calle M; David V
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):359-366. PubMed ID: 32452919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
    Vogt I; Haffner D; Leifheit-Nestler M
    Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?
    Oliveira RB; Cancela AL; Graciolli FG; Dos Reis LM; Draibe SA; Cuppari L; Carvalho AB; Jorgetti V; Canziani ME; Moysés RM
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):286-91. PubMed ID: 19965540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
    Rastogi A
    Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C; Roe K; Lehman E; Verma N
    Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Cai X; Lee J; Scialla JJ; Bansal N; Sondheimer JH; Chen J; Hamm LL; Ricardo AC; Navaneethan SD; Deo R; Rahman M; Feldman HI; Go AS; Isakova T; Wolf M;
    JAMA Cardiol; 2016 Aug; 1(5):548-56. PubMed ID: 27434583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT).
    Adema AY; de Jong MA; de Borst MH; Ter Wee PM; Vervloet MG;
    Nephron; 2016; 134(4):215-220. PubMed ID: 27442253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.
    Isakova T; Ix JH; Sprague SM; Raphael KL; Fried L; Gassman JJ; Raj D; Cheung AK; Kusek JW; Flessner MF; Wolf M; Block GA
    J Am Soc Nephrol; 2015 Oct; 26(10):2328-39. PubMed ID: 25967123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis.
    Takkavatakarn K; Wuttiputhanun T; Phannajit J; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
    Int Urol Nephrol; 2022 Feb; 54(2):309-321. PubMed ID: 33797709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphate Control: The Next Frontier in Dialysis Cardiovascular Mortality.
    McCullough PA
    Cardiorenal Med; 2021; 11(3):123-132. PubMed ID: 34120113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF23: a mature renal and cardiovascular risk factor?
    Zoccali C; Yilmaz MI; Mallamaci F
    Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Npt2b deletion attenuates hyperphosphatemia associated with CKD.
    Schiavi SC; Tang W; Bracken C; O'Brien SP; Song W; Boulanger J; Ryan S; Phillips L; Liu S; Arbeeny C; Ledbetter S; Sabbagh Y
    J Am Soc Nephrol; 2012 Oct; 23(10):1691-700. PubMed ID: 22859851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.
    Jovanovich A; Ix JH; Gottdiener J; McFann K; Katz R; Kestenbaum B; de Boer IH; Sarnak M; Shlipak MG; Mukamal KJ; Siscovick D; Chonchol M
    Atherosclerosis; 2013 Nov; 231(1):114-9. PubMed ID: 24125420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
    Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
    J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.